# EQRx Inc. (EQRX)

Source: https://www.quantisnow.com/company/EQRX
Generated: 2026-11-22T13:09:21.848Z

- Ticker: EQRX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: https://www.eqrx.com

## About

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

## Latest EQRX news and filings

- 2023-11-20 21:00 UTC [SEC Form 15-12G filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-eqrx-inc-5095898)
- 2023-11-20 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-eqrx-inc-5094507)
- 2023-11-20 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-eqrx-inc-5094498)
- 2023-11-20 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-eqrx-inc-5094497)
- 2023-11-17 21:23 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by EQRx Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-eqrx-inc-amendment-5093395)
- 2023-11-17 11:00 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by EQRx Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-eqrx-inc-amendment-5091661)
- 2023-11-15 22:27 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by EQRx Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-eqrx-inc-amendment-5088300)
- 2023-11-09 21:27 UTC [SEC Form 4] [Nallicheri Melanie returned 10,157,393 shares to the company and exercised 626,999 shares at a strike of $2.21, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/nallicheri-melanie-returned-10157393-shares-to-the-company-and-exercised-5075475)
- 2023-11-09 21:18 UTC [SEC Form 4] [SEC Form 4 filed by Merksamer Samuel J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-merksamer-samuel-j-5075285)
- 2023-11-09 21:18 UTC [SEC Form 4] [Berns Paul L returned 627,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/berns-paul-l-returned-627000-shares-to-the-company-closing-5075246)
- 2023-11-09 21:13 UTC [SEC Form 4] [Horning Sandra returned 470,250 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/horning-sandra-returned-470250-shares-to-the-company-closing-all-5075091)
- 2023-11-09 21:13 UTC [SEC Form 4] [Ciarimboli Dina returned 731,750 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/ciarimboli-dina-returned-731750-shares-to-the-company-closing-all-5075068)
- 2023-11-09 21:12 UTC [SEC Form 4] [SEC Form 4 filed by Yeshwant Krishna](https://www.quantisnow.com/insight/sec-form-4-filed-by-yeshwant-krishna-5075033)
- 2023-11-09 21:11 UTC [SEC Form 4] [Conde Jorge returned 53,064,157 shares to the company (SEC Form 4)](https://www.quantisnow.com/insight/conde-jorge-returned-53064157-shares-to-the-company-sec-form-5075013)
- 2023-11-09 21:09 UTC [SEC Form 4] [SEC Form 4 filed by Giusti Kathryn E](https://www.quantisnow.com/insight/sec-form-4-filed-by-giusti-kathryn-e-5074945)
- 2023-11-09 21:06 UTC [SEC Form 4] [SEC Form 4 filed by Ah Equity Partners Lsv I, L.L.C.](https://www.quantisnow.com/insight/sec-form-4-filed-by-ah-equity-partners-lsv-i-5074877)
- 2023-11-09 21:06 UTC [SEC Form 4] [Abernethy Amy returned 200,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/abernethy-amy-returned-200000-shares-to-the-company-closing-all-5074834)
- 2023-11-09 21:06 UTC [SEC Form 4] [SEC Form 4 filed by Meanwell Clive](https://www.quantisnow.com/insight/sec-form-4-filed-by-meanwell-clive-5074819)
- 2023-11-09 21:05 UTC [SEC Form POS AM filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-eqrx-inc-5074798)
- 2023-11-09 21:05 UTC [SEC Form 4] [SEC Form 4 filed by Ah Equity Partners Bio Ii, L.L.C.](https://www.quantisnow.com/insight/sec-form-4-filed-by-ah-equity-partners-bio-ii-5074761)
- 2023-11-09 21:05 UTC [SEC Form 4] [Borisy Alexis returned 18,810,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/borisy-alexis-returned-18810000-shares-to-the-company-closing-all-5074750)
- 2023-11-09 21:04 UTC [SEC Form POS AM filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-eqrx-inc-5074742)
- 2023-11-09 21:03 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-eqrx-inc-5074611)
- 2023-11-09 21:01 UTC [SEC Form POS AM filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-eqrx-inc-5074542)
- 2023-11-09 21:01 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-eqrx-inc-5074532)
- 2023-11-09 15:12 UTC [SEC Form 25-NSE filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-eqrx-inc-5073646)
- 2023-11-09 14:29 UTC [SEC Form 8-K] [EQRx Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eqrx-inc-filed-sec-form-8-k-completion-of-acquisition-or-5073528)
- 2023-11-08 16:33 UTC [Market Chatter] [Revolution Medicines And EQRx Stockholders Approve EQRx Acquisition](https://www.quantisnow.com/insight/revolution-medicines-and-eqrx-stockholders-approve-eqrx-acquisition-5069388)
- 2023-11-06 21:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-eqrx-inc-5062193)
- 2023-11-01 12:02 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-eqrx-inc-5049016)
- 2023-11-01 11:59 UTC [SEC Form 425] [SEC Form 425 filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-eqrx-inc-5048977)
- 2023-11-01 11:57 UTC [SEC Form 8-K] [SEC Form 8-K filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-eqrx-inc-5048918)
- 2023-10-23 10:13 UTC [SEC Form 425] [SEC Form 425 filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-eqrx-inc-5031514)
- 2023-09-29 20:38 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-eqrx-inc-4995300)
- 2023-08-16 12:07 UTC [SEC Form 425] [SEC Form 425 filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-eqrx-inc-4904554)
- 2023-08-08 21:29 UTC [SEC Form 425] [SEC Form 425 filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-eqrx-inc-4865261)
- 2023-08-08 21:20 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-eqrx-inc-4865125)
- 2023-08-06 00:13 UTC [Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA](https://www.quantisnow.com/insight/lifshitz-law-pllc-announces-investigations-of-eqrx-rvmd-newr-and-4851594)
- 2023-08-03 21:26 UTC [Market Insight] [EQRx In 8-K , Said  Provided Written Notice to G1 Therapeutics of Its Termination of the Exclusive License Agreement Dated July 22, 2020 Between EQRx and G1, Which Termination Will Be Effective in Accordance With the Terms of Such Agreement](https://www.quantisnow.com/insight/eqrx-in-8-k-said-provided-written-notice-to-g1-therapeutics-4845287)
- 2023-08-01 21:24 UTC [SEC Form 425] [SEC Form 425 filed by EQRx Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-eqrx-inc-4829364)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EQRX
- Earnings history: https://www.quantisnow.com/earnings/EQRX
- Dividend history: https://www.quantisnow.com/dividends/EQRX
- Insider transactions: https://www.quantisnow.com/insiders/EQRX
- Options chain: https://www.quantisnow.com/options/EQRX
- SEC 8-K filings only: https://www.quantisnow.com/company/EQRX/8-k
- RSS and alerts for EQRX: https://www.quantisnow.com/docs/rss-feeds.md
